Biologicals in osteoporosis: Teriparatide and parathyroid hormone in women and men

被引：9
作者：
Devogelaer J.-P. [1 ]
Boutsen Y. [2 ]
Manicourt D.H. [1 ]
机构：
[1] Department of Rheumatology, Université Catholique de Louvain, UCL 5390, St-Luc University Hospital, Brussels 1200
[2] Department of Rheumatology, Université Catholique de Louvain, Clinique Universitaire de Mont-Godinne
来源：
Current Osteoporosis Reports | 2010年 / 8卷 / 3期
关键词：
Alternate therapy; Bisphosphonate; Bone mineral density; Combined therapy; Fractures; Isolated therapy; Males; Markers of bone remodeling; Osteoporosis; Parathyroid hormone; Postmenopausal females; Raloxifene; Strontium ranelate;
D O I：
10.1007/s11914-010-0024-1
中图分类号：
学科分类号：
摘要：
Osteoporosis is characterized by the occurrence of a host of fractures. According to densitometric values, an operational definition for osteoporosis corresponds to a loss of 25% to 30% (-2.5 T-scores) compared with the mean values of bone mineral density of young premenopausal women. For years, research tried to develop drugs to improve the bone mineral density. According to the compounds, antiresorptive agents are able to decrease the fracture rate by about 30% to 70%, and to increase the bone mineral density. However, the agents increasing the most bone mineral density are not necessarily those that influence the most fracture rates. It has been known for years that parathyroid hormone (PTH) administered cyclically is able to increase bone mineral density. Two analogues of PTH have been developed: PTH (1-34) and PTH (1-84). Both of them are able to increase bone mineral density and reduce the rate of vertebral fracture but not of the hip, nor of nonvertebral fractures, the latter at least for PTH (1-84). Their exact place in the armamentarium of therapy of osteoporosis and their best time of administration are not yet definitely settled. New modes of administration (transdermal, intranasal, oral) will probably become available soon. With all the drugs available today and those still in development, it can be hoped that osteoporosis will become a disease of the past. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：154 / 161
页数：7
相关论文
共 60 条
[31]  
Miller P.D., Delmas P.D., Lindsay R., Et al., Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate, J Clin Endocrinol Metab, 93, pp. 3785-3793, (2008)
[32]  
Boonen S., Marin F., Obermayer-Pietsch B., Et al., Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis, J Clin Endocrinol Metab, 93, pp. 852-860, (2008)
[33]  
Keel C., Kraenzlin M.E., Kraenzlin C.A., Et al., Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice, J Bone Miner Metab, 28, pp. 68-76, (2010)
[34]  
Cosman F., Wermers R.A., Recknor C., Et al., Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: Differences between stopping and continuing the antiresorptive agent, J Clin Endocrinol Metab, 94, pp. 3772-3780, (2009)
[35]  
Cosman F., Nieves J., Zion M., Et al., Daily and cyclic parathyroid hormone in women receiving alendronate, N Engl J Med, 353, pp. 566-575, (2005)
[36]  
Adami S., San Martin J, Munoz-Torres M, et al.: Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis, Osteoporos Int, 19, pp. 87-94, (2008)
[37]  
Cosman F., Nieves J.W., Zion M., Et al., Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy, Osteoporos Int, 19, pp. 529-535, (2008)
[38]  
Kurland E.S., Cosman F., McMahon D.J., Et al., Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers, J Clin Endocrinol Metab, 85, pp. 3069-3076, (2000)
[39]  
Orwoll E.S., Scheele W.H., Paul S., Et al., The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis, J Bone Miner Res, 18, pp. 9-17, (2003)
[40]  
Devogelaer J.P., Glucocorticoid-induced osteoporosis: Mechanisms and therapeutic approach, Rheum Dis Clin N Am, 32, pp. 733-757, (2006)
123456